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Abstract
Background: Preoperative radio-chemotherapy (RCX) was introduced to improve the outcome of patients with oesophageal cancer (EC),
but conflicting results have been released. Some 20–30% of patients show a complete pathological response, however, the perioperative
morbidity and mortality is increased. To search for factors indicating response prior to the onset of RCX we investigated the proliferative
activity (MIB-1), the expression of vascular endothelial growth factor (VEGF), and the capillary density (CD34) in samples of EC obtained
by endoscopy prior to the start of the treatment. Methods: Forty-six (MIB-1) and 21 (VEGF, CD34) tissue specimens of ECs were available
from 56 patients undergoing pretherapeutic endoscopy, RCX and surgery. Perioperative morbidity was divided into surgery and non-surgery
related morbidity. MIB-1, VEGF and CD34 expression were investigated immunohistochemically. Multivariate analysis was carried out to
prove independence of investigated variables. Results: Postoperative morbidity was noticed in 54 of 56 operated patients. Eight of 56
patients who received RCX died in hospital. Survival was significantly different between the group of complete responders (n ¼ 14) and non-
responders (n ¼ 23; P ¼ 0:0026). None of the investigated tumour samples from patients with a complete response (CR) had a proliferation
index of less than 45. Tumour samples from patients with a CR showed a VEGF expression of 10.7 compared with 36.58 of tumours with no
response (P ¼ 0:035). CD34 expression showed a correlation with VEGF expression. The relation of mean indices of VEGF expression and
proliferative activity in tumours from patients with complete, partial or no response was 10.7:58.8, 18.3:53.8 and 36.6:43.5, respectively.
Conclusions: According to these results, it may be expected that tumours with a VEGF/MIB-1 ratio of 1:6 or less prior to RCX will respond
to this therapy. q 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The prognosis for patients with oesophageal cancer (EC)
remains poor with 5-year survival rates of 10–20% only. In
some selected patients, 5-year survival rates of 40% have
been reported after extended lymph node dissection [1].
Introduction of preoperative radio-chemotherapy (RCX)
may improve the overall survival rate, but conflicting results
have been released [2,3]. From a statistical point of view, at
least 450 patients need to be included in a controlled study
to demonstrate a 5-year survival benefit of 10–15% [4].
Most of the published studies include less patients. Never-
theless, an improvement of survival rates has been consis-
tently reported in many different studies in patients in whom
RCX led to a complete tumour response, defined as the
absence of vital tumour cells within the resected specimen
[5,6]. Three-year survival rates of .60% have been reported
in these patients. According to many phase II- and some
randomized phase III studies, a complete tumour response
can be expected in 20–30% [5–8] regardless of the applied
protocol, type of histology and tumour stage. On the other
hand, perioperative morbidity and mortality are increased
after RCX [8]. This affects all patients including those who
show only a partial or no response at all after preoperative
RCX. Therefore, identification of factors which predict a
response to RCX prior to the onset of this therapy are
urgently required.
Vascular endothelial growth factor (VEGF) is a potent
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mitogen for vascular endothelial cells derived from small
and large vessels but it is devoid of appreciable mitogenic
activity for other cell types. It is also able to induce angio-
genesis in a variety of in vivo models. In situ hybridization
studies have shown that the VEGF mRNA is markedly upre-
gulated in many human tumours including gastrointestinal
tract carcinomas. In all these tumours, VEGF mRNA is
expressed by tumour cells but not by endothelial cells. On
the other hand, the VEGF protein is detectable not only in
the tumour cells but also in blood vessels indicating an
accumulation of the tumour secreted VEGF within the target
cells. A correlation of VEGF expression with the T-stage
was reported in patients with EC [13]. The expression of
VEGF was inversely correlated with the 5-year survival rate
in squamous cell carcinoma of the oesophagus [14]. A
vascular network serves as a prerequisite for nutritional
supply for a growing tumour, otherwise the tumour becomes
necrotic or remains in a state of dormancy. Moreover,
angiogenesis provides a vascular route for haematogenous
spread of cancer cells to distant sites. The role of tumour
angiogenesis in the response to RCX is not yet defined.
Intramural microvessel density has been reported in EC
with conflicting results concerning the prognosis [10–12].
The aim of this study was to investigate the relation of
VEGF expression and vascular density in pretherapeutic
tumour biopsies with respect to preoperative RCX. In a
previous investigation, we have shown a correlation
between proliferative activity of tumour cells and histologi-
cally proven response in a small number of patients [9].
Extended data on proliferation indices expressed as a
percentage of MIB-1 positive tumour cells are presented
now using multivariate analysis for statistics. To our knowl-
edge this is the first study which examines the correlation of
the expression of VEGF, microvascular density and the
proliferative activity in EC with respect to outcome after
preoperative RCX. The results provide evidence that
tumours with a quotient of MIB-1/VEGF positive tumour
cells of .6:1 are likely to respond to preoperative RCX.
2. Materials and methods
From 1994 to 1998, 56 patients with EC were treated with
preoperative RCX and resection at the University Hospitals
of Freiburg. Fourteen patients had adenocarcinoma and 42
squamous cell carcinoma of the oesophagus (Table 1).
According to the treatment protocol, tumours invaded at
least the muscularis propria without evidence of distant
metastasis (T . 1, M0, UICC 1997). Clinical tumour
staging before the start of treatment consisted of endoscopy
with biopsy, endosonography, computed tomography, and
upper gastrointestinal contrast series. Lymph node enlarge-
ment of .1 cm was considered as malignant. All patients
were assessed clinically for operability as a precondition for
RCX. Pulmonary function was evaluated by spirometry,
cardiac function by echocardiography, cardiac stress tests,
and coronary angiography in patients with abnormal find-
ings. Liver and renal functions were assessed by laboratory
tests (aspartate aminotransferase, alkaline phosphatase,
serum bilirubin, blood urea and creatinine).
2.1. RCX
Radiotherapy was administered concomitantly with
chemotherapy for 4 weeks at 5 days/week. A total dose of
36 Gy was applied at daily fractions of 1.8 Gy on days 1–5
for 4 weeks. In addition, patients received 500 mg/m2 5-
fluorouracil on days 1–5 for 4 weeks and 20 mg/m2 cisplatin
on days 1–5 in the first and fourth week. After a break of at
least 4 weeks, restaging and resection were performed.
Response to preoperative RCX was determined by compar-
ing clinical tumour stage before the onset of treatment with
the pathological tumour stage as determined in the resected
specimen.
2.2. Surgical procedure
In most cases, a transthoracic approach (n ¼ 48) was used
for oesophageal resection including en-bloc lymphadenect-
omy. In some patients, a transhiatal approach (n ¼ 8) was
chosen mainly because of impaired lung function. In almost
all cases, reconstruction was performed by the stomach with
a cervical anastomosis in all patients. Only in a one patient a
colonic interposition graft was placed in the posterior
mediastinum. Details of operative procedures are given in
Table 1. Perioperative morbidity was divided into surgery
related and non-surgery related morbidity (Table 2).
In patients with no evidence of vital malignant cells
within the surgical specimen after RCX, a complete
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Table 1





Age (range) 58 (39–74)
Surgical approach: Transthoracic/transhiatal 48:8
Stage 3 28
Localization: distal/middle/upper 35:17:4
a n ¼ 56.
Table 2
Morbidity and mortality after preoperative RCX and resectiona
Morbidity RCX (%) Mortality (%)
Leakage 33.9 3.5
Recurrent nerve palsy/paresis 39.2 1.7
Other surgery related 14.3 5.3
Pneumonia 75.0 14.0
Mortality 14.3
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response (CR) was assumed. Tumour down-staging (either
change of lymph node involvement or reduction of tumour
infiltration) was classified as partial response (PR). No
change or tumour progress was classified as no response
(NR).
2.3. Biopsy specimens
Usually 4–6 samples/patient were obtained endoscopi-
cally to prove malignancy. Samples of 46 (MIB-1) and 21
(VEGF, CD34) patients with an EC were available under-
going pretherapeutic endoscopy. For control experiments,
sections from a follicular hyperplasia of a tonsil served as
positive control. The specimens were immediately
immersed in 4% unbuffered formalin and then prepared
according to standard methods. Serial sections of one
obtained sample/patient demonstrating the malignancy
were stained with hematoxylin and eosin (H&E) and peri-
odic acid Schiff and used for immunohistochemistry. After
quenching of endogenous peroxidase with 1% H2O2 for 30
min, serial sections were incubated with 0.5% normal
bovine serum to reduce non-specific background staining.
Thereafter, the slides were incubated with monoclonal anti-
bodies directed against MIF (dilution 1:600; DIANOVA,
Hamburg, Germany), CD34 (dilution 1:200, DAKO,
Hamburg, Germany), and polyclonal antibodies against
VEGF (dilution 1:1000; 1 mg/ml, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), respectively. For immunostaining all
slides were unmasked by pressure cooking in 10 mmol/l
citric acid, pH 6, for 5 min. Negative control experiments
were performed by replacing the primary antibodies with
preimmune serum of the corresponding species (mouse,
rabbit). All slides were then incubated with biotinylated
secondary antibody at room temperature, followed by incu-
bation with avidin and biotinylated horseradish peroxidase
complex (ABC-method, Vector, Burlingame, CA) as
previously described [25]. Peroxidase activity was visua-
lized by 3-amino-9-ethylcarbazole (AEC; Sigma, München,
Germany) to yield a brown reaction product. The nuclei
were slightly counterstained with hematoxylin.
2.4. Image processing
Five high-power fields ( £ 400)/slide (three slides/
patient) from each tumour specimen were analyzed by
light microscopy using a morphometric software (Analysis,
Softimaging Software GmbH, Münster, Germany). On aver-
age, 230 tumour cells/slide were counted. Tumour cells
were scored as positive or negative. Proliferating cells
were detected by positive staining for MIB-1. Calculation
of the proliferation index (PI) was performed as a percen-
tage of all tumour cells (Index ¼ positive tumour
cells £ 100/(positive 1 negative tumour cells)) [9]. All
results were reported as means ^ SD. Calculation of
VEGF index was performed accordingly.
Microvessel density was assessed in tumour areas show-
ing the strongest density of staining as determined by an
initial scan with low magnification [15]. For determination
of vessel density, five vascular areas/slide were counted
( £ 200) using the SIS-computer assisted analyzing software
package (Soft-Imaging Software GmbH, Münster,
Germany). The average counts were recorded.
2.5. Statistics
Survival rates (actuarial survival) were calculated by
Kaplan–Meier’s procedure, statistical differences were
calculated by Wilcoxon’s test, respectively; P , 0:05 was
regarded as significant. Differences in Chi square test of
numbers of stained cells were evaluated by the Student’s
t-test for independent samples. Multivariate analysis (Cox
procedure) was performed to prove independence of inves-
tigated variables. Sixteen variables were included (Table 3).
Stepwise forward and backward procedures were used to
strengthen the used models.
3. Results
Fifty-six patients were operated on for EC between 1994
and 1998 (51 men, five women) following RCX. The mean
age was 58 years (range, 39–75 years). Fourteen patients
had adenocarcinoma (25%) and 42 squamous cell carci-
noma (75%). In 35 patients, cancer was localized within
the lower third of the oesophagus. Preoperative staging
revealed stage 2 or 3 disease in most of the patients
(Table 1). Postoperative morbidity occurred in 54 of 56
patients, 22 patients suffered from a recurrent nerve palsy/
paresis combined with pneumonia. Eight of 56 patients died
in hospital after resection (14.3%; Table 2).
Fourteen patients (25%) showed a complete pathological
A. Imdahl et al. / European Journal of Cardio-thoracic Surgery 21 (2002) 657–663 659
Table 3




Localization Distal, middle, upper oesophagus
Histology Squamous, adenocarcinoma
Grading
Response NR, PR, CR
R R0, R1 1 2 (UICC 1987)
Morbidity Leakage, recurrent nerve palsy, other surgery
related, pneumonia
Mortality In hospital
Proliferative index Expressed as positive*100/total numbers of
tumour cells
VEGF index Expressed as positive*100/total numbers of
tumour cells
CD34 index Expressed as number of vessels/five fields in the
tumour area with strongest staining
CT Pretherapeutically
CN Pretherapeutically
PT Pathological after resection
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response (3/14 adenocarcinoma, 11/42 squamous cell carci-
noma). In 23 of 56 patients (41%), NR or even tumour
progress was observed (8/14 adenocarcinoma, 15/41 squa-
mous cell). There was no correlation between clinical
staging and response (Table 4). The calculated 5-year survi-
val rate of all 56 patients was 25% (median, 26 months). At
the last survey (10/2001), 26.8% of patients with a squa-
mous cell cancer were still alive (median, 18 months) and
50% of those with adenocarcinoma (median, 17 months;
P ¼ 0:5).
A significant difference (P ¼ 0:0026) in survival was
observed with regard to tumour response (including hospital
death, Fig. 1): 53.3% of patients were still alive after
complete pathological response (median, 54 months)
compared with 36.8% of patients with a PR (median, 40
months) and with 9.5% of those with no change/tumour
progress (median, 11 months). As numbers were too




In 46 of 56 patients who received preoperative RCX,
proliferative activity of tumour samples obtained prior to
RCX could be related to the response after resection.
Tumour samples of 13 patients with a complete pathological
response showed a mean PI of 58.81 compared with 53.98
and 45.9 of tumours with PR or NR (P ¼ 0:012). None of
the tumours with a CR had an index of less than 45 (Table
5). Correlation with survival was statistically significant: an
increased PI led to a better long-term survival (P ¼ 0:0114).
3.1.2. VEGF expression
Tumour cells exhibited a strong cytoplasmatic VEGF-
immunoreactivity (IR). In addition, capillaries within the
tumour revealed positive VEGF-IR staining of the endothe-
lial cells. VEGF expression could be determined in 21 biop-
sies prior to RCX. Tumour samples of five patients with a
complete pathological response showed a VEGF expression
index of 10.7 compared with 18.34 (n ¼ 8) and 36.58
(n ¼ 8) of tumours with PR or NR (P ¼ 0:035; Table 5).
Correlation with survival was statistically significant: a
decreased VEGF expression led to a better long-term survi-
val (P ¼ 0:0205).
3.1.3. CD34
Endothelial cells of the capillaries exhibited a strong
reaction with the CD34 antibody. In contrast, there was no
positive reaction at all with tumour cells. Tumour samples
of five patients with a complete pathological response
showed a CD34 index of 10.92 compared with 18.97
(n ¼ 8) and 18.16 (n ¼ 8) of tumours with PR or NR
(P ¼ 0:036). None of the tumours with a CR had an index
of more than 20 (Table 5). CD34 expression showed a corre-
lation with VEGF expression (r ¼ 0:4). Both vascular
density and VEGF expression were higher in tumour
samples which showed only PR or NR to preoperative
RCX compared with tumours from complete responders.
There was no correlation of CD34 expression with long-
term survival (P ¼ 0:63).
3.2. Correlation of proliferative activity and VEGF
expression
There was no direct correlation between the PI and the
VEGF expression of a respective specimen. In tumours
which showed a CR to chemoradiation, the relation of
mean indices between VEGF expression and proliferative
activity was 10.7–58.8 (Table 5). The relation of mean
indices of VEGF expression and proliferative activity in
tumours with PR or NR was 18.3–53.8 and 36.6–43.5,
respectively. According to these results, it may be expected
that tumours with a VEGF/MIB-1 quotient of 1:6 or less
prior to RCX will respond to this therapy.
Multivariate analysis revealed PI (P ¼ 0:0203), response
(P ¼ 0:0017) and tumour free resection (R0; P ¼ 0:023) as
independent variables for survival in patients who received
preoperative RCX. All other tested variables (sex, pT, pN,
histology, grading) were not significant. Logistic regression
defined PI (P ¼ 0:0193) and pN (P ¼ 0:0002) as indepen-
dent variables for tumour response in these patients.
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Table 4
Pretherapeutic, clinical staginga and CR after RCX and surgeryb
n CR Percentage
T2 18 8 44
T3 35 6 17
T4 3 0 0
N0 20 6 30
N1 36 8 22
a Clinical staging: T, N.
b No patient with clinically distant metastases (M1) received RCX.
Fig. 1. Actuarial survival rates of patients after preoperative RCX and
resection with respect to tumour response (n ¼ 56; last survey 10/2001).
CR, complete response after resection; PR, partial response; NR, no









 user on 29 August 2019
4. Discussion
It is still uncertain whether preoperative RCX leads to an
overall improvement of survival in patients with EC. Most
studies indicate that there may be a survival advantage for
patients with a complete pathological response which can be
expected in 20–30% of patients regardless of the applied
protocol [5,7].
Most studies published so far lack a sufficient patient
number, as from a statistical point of view, at least 450
patients need to be included in a controlled study to demon-
strate a 5-year survival benefit of 10–15% [4]. In addition, it
remains speculative whether variation of protocols may
increase the rate of complete responders.
The rate of CR in this study must be assessed carefully as
in eight patients a transhiatal approach was chosen for
reasons of impaired lung function. Lymph node clearance
in these patients was not as radical as in the transthoracic
approach. One of these eight patients revealed a complete
pathological response after the resection.
As CR after resection is clearly defined it is difficult to
assess PR. Tumour shrinkage of more than 50% is widely
regarded as major response, but assessment of lymph node
involvement is more difficult with the present staging proce-
dures. In most studies, lymph node enlargement of .1 cm is
regarded as malignancy which is not necessarily the case
[21]. Due to the unreliability of clinical staging and resta-
ging after RCX, PR is not further addressed in this paper.
Our data add further evidence that preoperative RCX
raises perioperative morbidity compared with a historical
control (data yet unpublished). It is our opinion that post-
operative complications after RCX are much more difficult
to treat than those occurring after resection without preo-
perative RCX, which is possibly related to an impaired
cellular immunity [22]. The increased perioperative morbid-
ity affects all patients who receive preoperative RCX,
including patients without any benefit from this therapy.
Moreover, RCX is time consuming and expensive. There-
fore, identification of factors are urgently required prether-
apeutically indicating response to RCX prior to the onset of
therapy.
Our data revealed great differences in the relation of mean
indices of VEGF expression and proliferative activity in
tumours with respect to the tumour response. Therefore,
we expect that tumours with a VEGF/MIB-1 ratio of 1:6
or less prior to RCX will respond to preoperative RCX.
A decrease of the standard uptake value (SUV) of posi-
tron emission tomography performed before the onset and
after RCX was correlated with response [24]. However,
whether changes in SUV can indicate response during preo-
perative RCX remains open. Conventional staging proce-
dures, clinical tumour stages or patient related factors
could not be correlated with tumour response [22].
On a molecular tumour related basis, there are only few
studies available which usually include only small numbers
of patients. Immunohistochemical staining for metallothio-
nein prior to the onset of RXC was inversely correlated with
tumour response after resection in patients with EC [23]. C-
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Table 5
PIa, VEGF expressionb and CD34 expressionb in tumour samples obtained prior start of RCX and correlated with response after resectionc,d
NR PR CR
MIB-1 VEGF CD34 MIB-1 VEGF CD34 MIB-1 VEGF CD34
23.53 n.t. n.t. 38.4 4.1 8.3 46.3 n.t. n.t.
23.64 n.t. n.t. 39.9 28.7 9.2 48.8 n.t. n.t.
25.57 18.1 13.3 40.3 10 10.6 51.0 n.t. n.t.
26.1 22.8 13.4 41.2 n.t. n.t. 52.4 6.1 5.2
27.18 45.3 14.2 46.2 32.3 13.1 53.2 n.t. n.t.
40.2 37.4 14.7 47 11.4 20.8 55.3 n.t. n.t.
44.9 35.3 15.7 47.2 22.3 191 59.4 n.t. n.t.
45.7 n.t. n.t. 50.9 19.3 34.7 61.4 32 8.3
51.8 n.t. n.t. 51.9 18.6 35.7 62.3 3.5 8.4
52.3 32.3 21.5 57.6 n.t. n.t. 66.4 8.2 14.5
52.8 n.t. n.t. 58.6 n.t. n.t. 69 n.t. n.t.
56.3 51.3 24.0 61.3 n.t. n.t. 69.2 n.t. n.t.
58.2 50.2 28.5 73.7 n.t. n.t. 70 3.7 18.2
60.4 n.t. n.t. 77.0 n.t. n.t.
62.9 n.t. n.t. 78.4 n.t. n.t.
63.1 n.t. n.t.
63.9 n.t. n.t.
Mean ^ SD Mean ^ SD Mean ^ SD Mean ^ SD Mean ^ SD Mean ^ SD Mean ^ SD Mean ^ SD Mean ^ SD
45.9 ^ 12.1 36.58 ^ 12.5 18.16 ^ 7.3 53.98 ^ 14.8 18.34 ^ 11.6 18.97 ^ 8.3 58.81 ^ 9.0 10.7 ^ 12.1 10.92 ^ 5.3
a MIB-1; n ¼ 46.
b n ¼ 21.
c Indices calculated as positive/total number of counted tumour cells (described in Section 2).
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erb 2 expression was inversely correlated with outcome
after preoperative RCX in patients with an EC [5].
Previously, we reported that in the CR group, none of the
investigated tumours showed a PI below 40% [9]. Apoptosis
investigated by terminal dUTP nick-end labelling (TUNEL)
did not correlate with response. We concluded, therefore,
that an imbalance of apoptosis and/or proliferation rate by
cells may eventually lead to tumour formation in cells which
become malignant for various reasons. Highly proliferative
cells with decreased activity of apoptosis grow faster than
cells with low proliferative activity and unchanged apopto-
sis. Tumours with an increased cell turnover seem to
respond more rapidly to RCX than tumours growing slowly.
We now present extended data on proliferation indices of
tumour samples prior to RCX thus confirming our earlier
results. In addition, multivariate analysis revealed MIB-1 as
an independent prognostic marker for tumour response.
Intratumoural microvessel density has been investigated
in EC with conflicting results concerning the prognosis [10–
12]. Angiogenetic factors such as VEGF are secreted by
tumour cells, thus regulating angiogenesis in tumours.
VEGF has been shown to be hypoxia-inducible in vitro in
different cultured cells and in vivo in a range of tissues
[16,17]. Moreover, expression of VEGF increased tumour
growth and angiogenesis in vivo in a nude mouse model
[18]. Also, anti-VEGF antibodies have the potential to
reduce growth of several tumour cell lines in nude mice
[19]. Whether the response to RCX in EC is influenced by
the expression of VEGF is unclear. The results of our study
suggest that tumours with low vessel density respond more
than those with high vessel density. Vessel density is depen-
dent on the expression of angiogenetic growth factors such
as VEGF. However, it is uncertain whether the expression of
VEGF by itself determines the reaction of a tumour to RCX
or whether expression of VEGF is indirectly related to
tumour response.
Interestingly, in a previous report, a correlation of PI
expressed as KI-67 labelling index with vessel density
could not be observed in patients with squamous cell carci-
noma [12]. Whilst this supports our findings, it may be
speculated that highly proliferative cells are likely to form
fast growing tumours and therefore need a vascular network
for nutritional supply. Probably anti-angiogenetic factors
keep the tumours in a state of dormancy [20] independent
of the proliferative activity of single tumour cells.
In conclusion, the results of our study confirm an
increased perioperative morbidity following preoperative
RCX in patients with EC. The CR rate was 25%, which
resulted in a significantly improved survival compared
with non-responders and with a historical control group.
The results obtained by immunohistochemistry suggest
that proliferative activity is positively while expression of
VEGF is inversely correlated with complete tumour
response. A relation of 1:6 or less of VEGF expression
and proliferative activity was predictive for a complete
tumour response in this retrospective study. However, data
have to be confirmed by a prospective investigation which is
currently performed.
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